SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-14 |
| Reported value | $307,788,414 |
| Positions | 13 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| VAXCYTE INC | PCVX | COM | $82,862,571 | 1,425,470 |
| ARCUTIS BIOTHERAPEUTICS INC | ARQT | COM | $33,175,720 | 1,265,283 |
| TREVI THERAPEUTICS INC | TRVI | COM | $32,500,833 | 1,742,672 |
| AVALYN PHARMACEUTICALS INC | AVLN | COM SHS | $31,826,793 | 966,792 |
| EVOMMUNE INC | EVMN | COM SHS | $25,609,072 | 1,926,943 |
| MAPLIGHT THERAPEUTICS INC | MPLT | COM | $21,914,225 | 611,446 |
| OCULIS HOLDING AG | OCS | ORDINARY SHARES | $20,891,688 | 1,506,250 |
| BIOAGE LABS INC | BIOA | COM | $16,014,197 | 653,374 |
| IMMUNOME INC | IMNM | COM | $15,521,929 | 732,512 |
| ZENAS BIOPHARMA INC | ZBIO | COM | $12,455,641 | 490,766 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.